Immunovant, Inc. financial data

Symbol
IMVT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
320 West 37 Th Street, New York, New York
State of incorporation
Delaware
Fiscal year end
March 31
Former names
Health Sciences Acquisitions Corp (to 12/20/2019)
Latest financial report
Q1 2024 - May 29, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17 K % -7.48%
Debt-to-equity 9.32 % +7.62%
Return On Equity -64.5 % -43.4%
Return On Assets -59.3 % -41.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 146 M shares +11.8%
Common Stock, Shares, Outstanding 146 M shares +11.7%
Entity Public Float 2.18 B USD +811%
Common Stock, Value, Issued 14 K USD +7.69%
Weighted Average Number of Shares Outstanding, Basic 138 M shares +12.2%
Weighted Average Number of Shares Outstanding, Diluted 138 M shares +12.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 128 M USD +60.3%
General and Administrative Expense 57.3 M USD +19.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -259 M USD -22.7%
Income Tax Expense (Benefit) 567 K USD +6200%
Net Income (Loss) Attributable to Parent -259 M USD -22.9%
Earnings Per Share, Basic -1.88 USD/shares -9.94%
Earnings Per Share, Diluted -1.88 USD/shares -9.94%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 635 M USD +68.7%
Accounts Receivable, after Allowance for Credit Loss, Current 5.34 M USD +662%
Assets, Current 666 M USD +64.7%
Property, Plant and Equipment, Net 462 K USD +38.7%
Operating Lease, Right-of-Use Asset 133 K USD -88.7%
Assets 666 M USD +64.2%
Accounts Payable, Current 7.16 M USD +429%
Accrued Liabilities, Current 41.3 M USD +2.18%
Liabilities, Current 48.6 M USD +12.3%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 48.6 M USD +12.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.91 M USD +124%
Retained Earnings (Accumulated Deficit) -826 M USD -45.8%
Stockholders' Equity Attributable to Parent 618 M USD +70.4%
Liabilities and Equity 666 M USD +64.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -214 M USD -13.8%
Net Cash Provided by (Used in) Financing Activities 472 M USD +566%
Net Cash Provided by (Used in) Investing Activities -360 K USD -82.7%
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 146 M shares +11.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 259 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 635 M USD +68.7%
Deferred Tax Assets, Valuation Allowance 141 M USD +53.8%
Deferred Tax Assets, Gross 142 M USD +53.3%
Operating Lease, Liability 138 K USD -88.7%
Depreciation 231 K USD +19.7%
Payments to Acquire Property, Plant, and Equipment 360 K USD +82.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -258 M USD -22.7%
Lessee, Operating Lease, Liability, to be Paid 141 K USD -88.7%
Operating Lease, Liability, Current 138 K USD -88.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 47 K USD -96.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 141 K USD -88.2%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3 K USD -88%
Lessee, Operating Lease, Liability, to be Paid, Year Three 47 K USD -95.8%
Deferred Tax Assets, Operating Loss Carryforwards 98.2 M USD +52.5%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 567 K USD +6200%
Preferred Stock, Shares Authorized 10 M shares 0%
Operating Lease, Payments 1.2 M USD 0%
Additional Paid in Capital 1.44 B USD +55.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 347 K USD -30.9%
Share-based Payment Arrangement, Expense 41 M USD +28.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%